Literature DB >> 8274196

Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells.

G Parmiani1.   

Abstract

Oncogenic transformation is often accompanied by a significant overproduction of otherwise normal cellular proteins. Because of the low expression of such self components during thymic development, T cells specific for these antigens can escape deletion and progress to the periphery. In this viewpoint, Giorgio Parmiani discusses the concept that these T cells can be harnessed to provide an effective anti-tumor response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8274196     DOI: 10.1016/0167-5699(93)90183-L

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  12 in total

Review 1.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

2.  Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients.

Authors:  X Q Huang; M S Mitchell; P E Liggett; A L Murphree; J Kan-Mitchell
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

3.  CD4+ Th0 cell clones, isolated from a metastatic lymph node of a melanoma patient, possess cytolytic function.

Authors:  M A Imro; C Castagneto; O Bosco; P Modena; L Lanza; F Puppo; G Filaci; F Indiveri; M Scudeletti
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

4.  Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells.

Authors:  Björn Schöttker; Ingo G H Schmidt-Wolf
Journal:  Ger Med Sci       Date:  2011-08-04

5.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.

Authors:  J I Mayordomo; D J Loftus; H Sakamoto; C M De Cesare; P M Appasamy; M T Lotze; W J Storkus; E Appella; A B DeLeo
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

6.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.

Authors:  D Boczkowski; S K Nair; D Snyder; E Gilboa
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

7.  The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.

Authors:  Vanesa Alonso-Camino; Karishma Rajani; Timothy Kottke; Diana Rommelfanger-Konkol; Shane Zaidi; Jill Thompson; Jose Pulido; Elizabeth Ilett; Oliver Donnelly; Peter Selby; Hardev Pandha; Alan Melcher; Kevin Harrington; Rosa Maria Diaz; Richard Vile
Journal:  Mol Ther       Date:  2014-07-25       Impact factor: 11.454

8.  Trial watch: Peptide vaccines in cancer therapy.

Authors:  Erika Vacchelli; Isabelle Martins; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

9.  Trial watch: DNA vaccines for cancer therapy.

Authors:  Laura Senovilla; Erika Vacchelli; Pauline Garcia; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

10.  Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

Authors:  R F Wang; P F Robbins; Y Kawakami; X Q Kang; S A Rosenberg
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.